Literature DB >> 14961859

Growth rate of non-vestibular intracranial schwannomas.

B F O'Reilly1, H Mehanna, A Kishore, J A Crowther.   

Abstract

A group of nine patients with non-vestibular intracranial neuromas (four jugular, four facial, one trigeminal) underwent an interval scanning management policy, with serial annual magnetic resonance (MR) imaging. Tumour volume was assessed by manual measurement of the tumour area by MR imaging. Tumour volume was assessed by manual measurement of the tumour area on MR imaging axial cuts. The mean tumour size at presentation was 4.6 cm(3) (range 0.7-17.8 cm(3)). During a mean follow-up of 36 months (range 22-50 months), five out of nine tumours grew significantly at a rate of more than 5% of their initial volume per year. Only those tumours growing at a rate of more than 20% initial volume per year exhibited symptom progression. During a 36-month period of interval scanning, just over 50% of non-vestibular intracranial neuromas exhibited significant growth. Symptom progression was found to be a strong indicator of a high growth rate. This proportion exhibiting growth is higher than that demonstrated by unilateral sporadic vestibular schwannomas, but less than in patients with neurofibromatosis II. Early treatment of non-vestibular intracranial neuromas should therefore be considered.

Entities:  

Mesh:

Year:  2004        PMID: 14961859     DOI: 10.1111/j.1365-2273.2004.00770.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  4 in total

1.  Multimodality Management of Trigeminal Schwannomas.

Authors:  Ajay Niranjan; Samuel Barnett; Vijay Anand; Siviero Agazzi
Journal:  J Neurol Surg B Skull Base       Date:  2016-04-22

2.  Psychiatric Disease Preceding Intracranial Tumor Diagnosis: Investigating the Association.

Authors:  Kathryn R Tringale; Bayard R Wilson; Brian Hirshman; Tianzan Zhou; David Folsom; Marc A Norman; Igor Grant; Clark C Chen; Bob S Carter
Journal:  Prim Care Companion CNS Disord       Date:  2016-12-15

3.  Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants.

Authors:  Daniel Moualed; Jonathan Wong; Owen Thomas; Calvin Heal; Rukhtam Saqib; Cameron Choi; Simon Lloyd; Scott Rutherford; Emma Stapleton; Charlotte Hammerbeck-Ward; Omar Pathmanaban; Roger Laitt; Miriam Smith; Andrew Wallace; Mark Kellett; Gareth Evans; Andrew King; Simon Freeman
Journal:  Eur J Hum Genet       Date:  2022-01-24       Impact factor: 4.246

Review 4.  Trends in the Management of Non-Vestibular Skull Base and Intracranial Schwannomas.

Authors:  Carlos Suárez; Fernando López; William M Mendenhall; Simon Andreasen; Lauge Hjorth Mikkelsen; Johannes A Langendijk; Stefano Bondi; Juan P Rodrigo; Leif Bäck; Antti A Mäkitie; Verónica Fernández-Alvarez; Andrés Coca-Pelaz; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.